Objective To manufacture a new-type ultrasound contrast agent which had the specificity of liver targeting—-- perfluorooctyl bromide lipid nanoparticle with Galactocylated Poly-L-Lysine（Gal-PLL），to study its liver targeting ability in vitro. Methods The preparation of high-efficiency Galactocylated Poly-L-Lysine（Gal-PLL）ligand of the asialoglycoprotein receptor in liver was optimized by Chemical reactions of reductive amination. Lipid membrane prepared before was eluted with Gal-PLL，adding PFOB in it， then objective ultrasound contrast agent was manufactured by means of ultrasonic cell disruptor agitation，observing its feature，detecting the grain diameter and electric potential. Targeting contrast agent（experimental group） and non-targeting contrast agent（control group） were instilled into normal rat hepatocyte BRL and normal human hepatocyte L02 which grew with adherence，observing the two groups’targeting effect of the contrast agent and the cell. Results High-efficiency Gal-PLL ligand of the asialoglycoprotein receptor in liver was successfully prepared and novel ultrasound contrast agent—--perfluorooctyl bromide lipid nanoparticle was manufactured. Its shape under the electron microscope was rounded and the same size ，it had stable nature also. Its average diameter was 200 nm, and its average electric potential was 35 mV. The contrast agent can flock together around the BRL and LO2 cells because of its targeting effect. Conclusion Manufactured novel ultrasound contrast agent—--perfluorooctyl bromide lipid nanoparticle had many advantages，such as targeting and stable nature. These advantages provided a primary foundation for future study of ultrasonic contrast of real time monitoring in vivo and quantitative assessment of the liver damage degree.